Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study

被引：0

作者：

Piedra, A. ^{[1
]}

Recio, S. Martinez ^{[1
]}

Gonzalez, A. Hernandez ^{[2
]}

Bueno, M. T. Moran ^{[2
]}

Arriola, E. ^{[3
]}

Recuero-Borau, J. ^{[4
]}

Dols, M. Cobo ^{[5
]}

Gonzalez, P. Cordeiro ^{[6
]}

Martinez, J. Mosquera ^{[7
]}

Garcia-Campelo, M. R. ^{[7
]}

Blanco, A. Calles ^{[8
]}

Alvarez, R. M. ^{[8
]}

Garcia, M. Zapata ^{[9
]}

Casado, M. D. Isla ^{[9
]}

Perez, A. Callejo ^{[10
]}

Gomez, P. Iranzo ^{[10
]}

Joaquin, A. Barba ^{[1
]}

Sullivan, I. G. ^{[1
]}

Felip, E. ^{[11
]}

Majem, M. ^{[1
]}

机构：

[1] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain

[2] Hosp Badalona Germans Trias & Pujol, Dept Med Oncol, ICO Inst Catala Oncol Badalona, Badalona, Spain

[3] Hosp Mar CIBERONC, Dept Med Oncol, Barcelona, Spain

[4] Hosp Mar Parc Salut Mar, Dept Med Oncol, Barcelona, Spain

[5] Hosp Reg Univ Malaga Carlos Haya, Dept Med Oncol, Malaga, Spain

[6] Inst Invest Biomed Coruna INIBIC, Dept Med Oncol, La Coruna, Spain

[7] CHUAC Complexo Hosp Univ A Coruna, Dept Med Oncol, La Coruna, Spain

[8] Hosp Gen Univ Gregorio Maranon, Dept Med Oncol, Madrid, Spain

[9] Hosp Clin Univ Lozano Blesa, Dept Med Oncol, Zaragoza, Spain

[10] Vall Hebron Univ Hosp VHIO, Dept Med Oncol, Barcelona, Spain

[11] Vall Hebron Univ Hosp VHIO, Med Oncol Serv, Lung Canc Unit, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2507

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1476P

引用

页数：2

共 50 条

[1] Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
Cortellini, Alessio
Tiseo, Marcello
Banna, Giuseppe L.
Cappuzzo, Federico
Aerts, Joachim G. J., V
Barbieri, Fausto
Giusti, Raffaele
Bria, Emilio
Cortinovis, Diego
Grossi, Francesco
Migliorino, Maria R.
Galetta, Domenico
Passiglia, Francesco
Santini, Daniele
Berardi, Rossana
Morabito, Alessandro
Genova, Carlo
Mazzoni, Francesca
Di Noia, Vincenzo
Signorelli, Diego
Tuzi, Alessandro
Gelibter, Alain
Marchetti, Paolo
Macerelli, Marianna
Rastelli, Francesca
Chiari, Rita
Rocco, Danilo
Gori, Stefania
De Tursi, Michele
Mansueto, Giovanni
Zoratto, Federica
Santoni, Matteo
Tudini, Marianna
Rijavec, Erika
Filetti, Marco
Catino, Annamaria
Pizzutilo, Pamela
Sala, Luca
Citarella, Fabrizio
Marco, Russano
Torniai, Mariangela
Cantini, Luca
Targato, Giada
Sforza, Vincenzo
Nigro, Olga
Ferrara, Miriam G.
D'Argento, Ettore
Buti, Sebastiano
Bordi, Paola
Antonuzzo, Lorenzo
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (11) : 2209 - 2221
[2] Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
Alessio Cortellini
Marcello Tiseo
Giuseppe L. Banna
Federico Cappuzzo
Joachim G. J. V. Aerts
Fausto Barbieri
Raffaele Giusti
Emilio Bria
Diego Cortinovis
Francesco Grossi
Maria R. Migliorino
Domenico Galetta
Francesco Passiglia
Daniele Santini
Rossana Berardi
Alessandro Morabito
Carlo Genova
Francesca Mazzoni
Vincenzo Di Noia
Diego Signorelli
Alessandro Tuzi
Alain Gelibter
Paolo Marchetti
Marianna Macerelli
Francesca Rastelli
Rita Chiari
Danilo Rocco
Stefania Gori
Michele De Tursi
Giovanni Mansueto
Federica Zoratto
Matteo Santoni
Marianna Tudini
Erika Rijavec
Marco Filetti
Annamaria Catino
Pamela Pizzutilo
Luca Sala
Fabrizio Citarella
Russano Marco
Mariangela Torniai
Luca Cantini
Giada Targato
Vincenzo Sforza
Olga Nigro
Miriam G. Ferrara
Ettore D’Argento
Sebastiano Buti
Paola Bordi
Lorenzo Antonuzzo
Cancer Immunology, Immunotherapy, 2020, 69 : 2209 - 2221
[3] Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line
Zhao, Yue
Mao, Yousheng
He, Jie
Gao, Shugeng
Zhang, Zhirong
Ding, Ningning
Xue, Qi
Gao, Yushun
Wang, Dali
Zhao, Jun
Tan, Fengwei
Yuan, Ligong
Li, Feng
Wang, Shuaibo
Yang, Lin
CLINICAL LUNG CANCER, 2021, 22 (02) : E201 - E210
[4] KEYNOTE-042 China Study: First-Line Pembrolizumab vs Chemotherapy in Chinese Patients with Advanced NSCLC with PD-L1 TPS ≥1%
Wu, Y.
Zhang, L.
Fan, Y.
Zhou, J.
Zhang, L.
Zhou, Q.
Li, W.
Hu, C.
Chen, G.
Zhang, X.
Zhou, C.
Dang, T.
Penrod, J.
Kush, D.
Qin, Y.
Li, B.
Mok, T.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S290 - S291
[5] Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
Aguilar, E. J.
Ricciuti, B.
Gainor, J. F.
Kehl, K. L.
Kravets, S.
Dahlberg, S.
Nishino, M.
Sholl, L. M.
Adeni, A.
Subegdjo, S.
Khosrowjerdi, S.
Peterson, R. M.
Digumarthy, S.
Liu, C.
Sauter, J.
Rizvi, H.
Arbour, K. C.
Carter, B. W.
Heymach, J. V.
Altan, M.
Hellmann, M. D.
Awad, M. M.
ANNALS OF ONCOLOGY, 2019, 30 (10) : 1653 - 1659
[6] Phase III Trial of Pembrolizumab-Chemotherapy Versus Pembrolizumab in First-Line of Advanced NSCLC with PD-L1 ≥50%: PERSEE
Descourt, R.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1011 - S1011
[7] First-Line Approval Extension New Treatment Option for Patients with NSCLC and high PD-L1 Expression
Kohl, Angelika
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (7-8) : 434 - 434
[8] Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC
Kilickap, S.
Sezer, A.
Gumus, M.
Bondarenko, I.
Ozguroglu, M.
Gogishvili, M.
Turk, H. M.
Cicin, I.
Bentsion, D.
Gladkov, O.
Clingan, P.
Sriuranpong, V.
Rizvi, N.
Li, S.
Lee, S.
Makharadze, T.
Paydas, S.
Nechaeva, M.
Seebach, F.
Weinreich, D. M.
Yancopoulos, G. D.
Gullo, G.
Lowy, I.
Rietschel, P.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S101 - S101
[9] First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
Zhou, Yixin
Lin, Zuan
Zhang, Xuanye
Chen, Chen
Zhao, Hongyun
Hong, Shaodong
Zhang, Li
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[10] Predictive factors of efficacy to pembrolizumab in advanced NSCLC patients with high PD-L1 expression.
Piedra, A.
Barba Joaquin, A.
Mosquera Martinez, J.
Fernandez Bruno, M.
Cordeiro Gonzalez, P.
Sullivan, I. G.
Riudavets Melia, M.
Aguado Sorolla, M.
Gallardo Melo, P.
Martin Cullell, B.
Gavira, J.
Tapia, J. C.
Romano, A.
Bosma, F.
Sanchez Del Rio, S.
Sanz Beltran, J.
Molina Perez, M. A.
Serra Lopez, J.
Garcia Campelo, M. R.
Majem Tarruella, M.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1053 - S1053

← 1 2 3 4 5 →